HealthcareServices

Next-Generation Antibody Therapeutics Market Research: Growth Projections and Trends 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the next-generation antibody therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Next-Generation Antibody Therapeutics Market be in 2030 compared with 2026?_x000D_

The market for next-generation antibody therapeutics has observed rapid expansion in recent years. It is anticipated to increase from $7.56 billion in 2025 to $8.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.4%. The historical surge in this market can be linked to factors such as an uptick in monoclonal antibody approvals, a rise in cancer cases, the enlargement of biologics manufacturing capabilities, greater investment in pharmaceutical R&D, and more streamlined regulatory processes for biologics._x000D_

_x000D_

The next-generation antibody therapeutics market size is anticipated to experience swift expansion in the coming years, with projections indicating a growth to $12.63 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.9%. This upward trend over the forecast period is propelled by advancements in antibody engineering technologies, an increasing need for targeted therapies, the rising occurrence of chronic and autoimmune diseases, the expansion of clinical trials within emerging markets, and growing collaborations between biotech and pharmaceutical companies. Significant developments expected during this timeframe involve the broadening of bispecific and multispecific antibody platforms, the increasing utilization of antibody-drug conjugates in oncology, a heightened emphasis on high-affinity and long-acting antibodies, a burgeoning clinical pipeline for rare and orphan diseases, and a noticeable shift toward personalized antibody-based treatments._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp_x000D_

_x000D_

What Drivers Are Guiding Growth Patterns In The Next-Generation Antibody Therapeutics Market?_x000D_

The escalating incidence of chronic ailments is anticipated to fuel the expansion of the next-generation antibody therapeutics market in the future. These conditions are defined as health issues persisting for at least a year, requiring ongoing medical intervention, limiting daily functions, or a combination of these factors. Next-generation antibody therapeutics offer a treatment approach for individuals suffering from chronic illnesses, providing more targeted care and thereby improving patient outcomes. As an illustration, data from January 2023, released by the National Center for Biotechnology Information (NCBI), a US National Library of Medicine, indicated a forecast that by 2050, the population aged 50 years and older afflicted with at least one chronic condition is expected to increase by 99.5%, reaching 142.66 million. Consequently, the rising occurrence of chronic diseases is a key factor propelling the expansion of the next-generation antibody therapeutics market._x000D_

_x000D_

How Is The Next-Generation Antibody Therapeutics Market Divided Into Segments?_x000D_

The next-generation antibody therapeutics market covered in this report is segmented –_x000D_

_x000D_

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types_x000D_

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas_x000D_

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies_x000D_

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies_x000D_

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies_x000D_

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types_x000D_

5) By Other Types: Nanobodies, Engineered Antibodies_x000D_

_x000D_

Which Trends Are Guiding The Evolution Of The Next-Generation Antibody Therapeutics Market?_x000D_

Leading companies within the next-generation antibody therapeutics market are concentrating on developing technological advancements, such as their proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology, to improve protein identification and characterization, thereby enabling more targeted and effective treatments. These innovations are consequently designed to enhance therapeutic profiles, reduce costs, and address complex diseases with greater precision. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a method that organizes protein molecules into structured assemblies, allowing for improved analysis and quantification. This approach increases sensitivity and accuracy in detecting proteins, which is valuable in both research and diagnostics. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, introduced a next-generation antibody profiling platform that leverages MIPSA technology for high-throughput, cost-effective analysis of immune responses, with the goal of deepening disease understanding and personalizing treatment strategies._x000D_

_x000D_

Which Leading Companies Dominate The Next-Generation Antibody Therapeutics Market Share?_x000D_

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed_x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report_x000D_

_x000D_

Which Region Is Anticipated To See The Fastest Growth In The Next-Generation Antibody Therapeutics Market?_x000D_

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Next-Generation Antibody Therapeutics Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company#_x000D_

_x000D_

Monoclonal Antibodies Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report_x000D_

_x000D_

Antibody Discovery Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report_x000D_

_x000D_